New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 6, 2014
07:27 EDTCUBI, FARO, EGHT, AME, KWR, ETM, CASH, ALNY, GSVC, EPAM, BMTCEmerald Advisers to hold a forum
21st Groundhog Day Investment Forum is being held in Philadelphia on Feburary 6.
News For ALNY;AME;BMTC;CASH;EGHT;EPAM;ETM;FARO;GSVC;KWR;CUBI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 20, 2014
07:20 EDTCUBIFurey Research Partners to hold a conference
Subscribe for More Information
07:03 EDTFAROFARO Technologies initiated with a Buy at Canaccord
Target $65.
November 19, 2014
07:52 EDTALNYInforma Business Information to hold a conference
Subscribe for More Information
November 18, 2014
07:36 EDTEPAMUBS to hold a conference
Global Technology Conference to be held in Sausalito, California on November 18-20 with webcasted company presentations to begin on November 18 at 10:45 am; not all company presentations may be webcasted. Webcast Link
November 17, 2014
20:39 EDTEGHT8x8, Inc. management to meet with William Blair
Subscribe for More Information
17:03 EDTALNYAlnylam presents new pre-clinical data on RNAi therapeutic programs
Subscribe for More Information
07:59 EDTEPAMEPAM Systems price target raised to $60 from $50 at Cowen
Cowen raised its price target on EPAM Systems to $60 from $50 citing the company's strong fundamentals, pipeline, and visibility. Cowen reiterated its Outperform rating on EPAM Systems shares.
07:09 EDTALNYAmerican Heart Association to hold a conference
Subscribe for More Information
November 14, 2014
06:31 EDTALNYAlnylam to host conference call
Subscribe for More Information
06:04 EDTALNYAlnylam announces positive initial phase 2 data with Revusiran
Alnylam announced positive initial Phase 2 data with revusiran, an investigational RNAi therapeutic targeting transthyretin for the treatment of TTR cardiac amyloidosis. In the pilot Phase 2 study, revusiran was found to be generally well tolerated in TTR cardiac amyloidosis patients. Revusiran demonstrated clinical activity with an up to 98.2% knockdown of serum TTR – the disease causing protein. This included similar knockdown effects toward wild type and mutant TTR protein within V122I patients, who represent the most common genotype associated with inherited forms of TTR cardiac amyloidosis. In the five week course of treatment, there were no significant changes observed in a number of exploratory clinical measurements. Revusiran utilizes Alnylam’s proprietary GalNAc-conjugate delivery platform that enables subcutaneous delivery of RNAi therapeutics with a wide therapeutic index. The primary objective of the study was to evaluate the safety and tolerability of revusiran. The secondary objectives were to assess the clinical activity of revusiran toward serum levels of TTR and characterize the drug’s pharmacokinetic profile. In addition, a number of exploratory clinical measurements were performed at baseline and days 42 and 90 after start of dosing.
November 13, 2014
13:52 EDTAMEAmetek earns 'solid' returns on acquisitions, says Oppenheimer
After Spruce Point Capital issued a negative report on Ametek, Oppenheimer offered a response and kept an Outperform rating on the stock. Opco says Ametek earns "solid" returns on acquisitions while its inventory turns remain consistent with historical levels. The firm says the report contains "arbitrary correlations." Shares of Ametek are down 4% to $50.13 in afternoon trading.
10:27 EDTAMEHigh option volume stocks
Subscribe for More Information
09:37 EDTAMEAmetek mentioned cautiously by Spruce Point
Spruce Point issued a cautious report on Ametek and placed a "Strong Sell" rating and $27-$36 price target on the stock. Reference Link
November 11, 2014
08:16 EDTEGHT8x8, Inc. appoints Enzo Signore as Chief Marketing Officer
8x8, Inc. announced the appointment of enterprise communications industry veteran Enzo Signore as SVP and Chief Marketing Officer. Signore will report directly to 8x8 CEO Vik Verma and will be responsible for the strategy and execution of 8x8’s global marketing efforts. Signore was most recently VP of Worldwide Enterprise Solutions and Field Marketing at Avaya.
08:03 EDTALNYAlnylam adds ALN-HDV, ALN-PDL to hepatic infectious disease pipeline
Subscribe for More Information
November 10, 2014
07:20 EDTFARORW Baird to hold a conference
Subscribe for More Information
November 9, 2014
14:09 EDTALNYAlnylam management to meet with Needham
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use